醒脑静注射液治疗慢性阻塞性肺疾病急性加重期呼吸衰竭临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R563.9

基金项目:


Clinical Study on Xingnaojing Injection for Acute Exacerbation of Chronic Obstructive Pulmonary Disease Complicated with Respiratory Failure
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察醒脑静注射液辅助治疗慢性阻塞性肺疾病急性加重期(AECOPD) 合并Ⅱ型呼吸衰竭的临床疗效。方法:将AECOPD 合并Ⅱ型呼吸衰竭患者200 例随机分为观察组和对照组,各100 例;对照组采用西医常规联合无创正压通气治疗,观察组在对照组的基础上加用醒脑静注射液治疗,2 组均连续治疗7 d;观察比较2 组治疗前后血清白细胞介素-6(IL-6)、白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)、氧分压(PO2)、二氧化碳分压(PCO2)、pH 水平变化,评价2 组慢性阻塞性肺疾病评估量表(CAT) 评分及总体临床疗效。结果:总有效率观察组为91.00%,对照组为80.00%,2 组比较,差异有统计学意义(P<0.05)。治疗后,2 组患者血清IL-6、IL-10、TNF-α 水平均较治疗明显降低(P<0.05),且观察组各项指标均低于对照组(P<0.05)。治疗后,2 组患者动脉血气指标PO2、PCO2 值均较治疗前明显改善(P<0.05),且观察组两项指标改善较对照组更显著(P<0.05);2 组治疗前后pH 值则变化不大(P>0.05)。治疗后,2 组CAT 评分均较治疗明显降低(P<0.05),且观察组CAT 评分低于对照组(P<0.05)。结论:在西医常规及无创正压通气治疗的基础上,对AECOPD 合并Ⅱ型呼吸衰竭患者应用醒脑静注射液辅助治疗效果显著,可有效抑制患者炎症反应,改善血气指标,从而提高患者生活质量。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Xingnaojing injection in adjuvant therapy for acute exacerbation of chronic obstructive pulmonary disease(AECOPD) complicated with respiratory failure typeⅡ. Methods:A total of 200 case of patients with AECOPD complicated with respiratory failure typeⅡ were randomly divided into the observation group and the control group,100 cases in each group. The control group was given routine western medicine combined with noninvasive positive pressure ventilation, and the observation group was additionally treated with Xingnaojing injection based on the treatment of the control group. Both groups were continuously treated for seven days. The changes in the levels of interleukin- 6(IL-6),interleukin-10(IL-10),tumor necrosis factor-α(TNF-α),oxygen partial pressure(PO2),partial pressure of carbon dioxide(PCO2) and pH before and after treatment in the two groups were observed and compared. The scores of COPD assessment test(CAT) and total clinical effect were evaluated in the two groups. Results:The total effective rate was 91.00% in the observation group,and 80.00% in the control group,the difference being significant(P<0.05). After treatment,the levels of IL-6,IL-10 and TNF-α in the two groups were significantly decreased when compared with those before treatment (P<0.05), and the three levels in the observation group were lower than those in the control group(P<0.05). After treatment, the indexes of arterial blood gas, namely POB and PCO2 in the two groups were significantly improved when compared with those before treatment(P<0.05),and the improvement in the observation group was more significant than that in the control group(P<0.05);no significant change was found in the comparison of pH in the two groups before and after treatment(P>0.05). After treatment,the scores of CAT in the two groups were significantly decreased when compared with those before treatment(P<0.05),and the score in the observation group was lower than that in the control group(P< 0.05). Conclusion: Based on routine western medicine and noninvasive positive pressure ventilation, Xingnaojing injection has significant curative effect in the adjuvant therapy of AECOPD complicated with respiratory failure type Ⅱ, which can effectively inhibit inflammatory reaction,improve blood gas indexes,and thus enhance the quality of life.

    参考文献
    相似文献
    引证文献
引用本文

朱先锋.醒脑静注射液治疗慢性阻塞性肺疾病急性加重期呼吸衰竭临床研究[J].新中医,2020,52(17):61-63

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2020-09-06
  • 出版日期: